PathAI

Love is in the air and in the lab! 💌 Happy Valentine’s Day from PathAI. Here’s to collaborations, partnerships, and connections that spark passion and discovery ❤️ #HappyValentinesDay #Pathology #DigitalPathology #AI

👩🔬 This year is the 10th anniversary of the International Day of Women and Girls in Science (#IDWGS), a celebration #diversity in #STEM fields and a call to action for continued progress. In honor of #IDWGS2025, we’re highlighting insights from five women in science working at PathAI in a variety of ways. We asked them what inspired them to get into science, what they love about the field, and their hopes for their scientific work at PathAI—read on to hear more in their own words. Featuring Christina Jayson, Ph.D., Ylaine Gerardin, Jacqueline Brosnan-Cashman, Ph.D., Abigail Emerson, and Shima Nofallah #WomenInSTEM

🇧🇷 We're thrilled to announce a strategic partnership with Rede D'Or São Luiz, the largest health system in Brazil, to bring AI-powered #digitalpathology solutions to South America 📝 Read the Press Release: https://lnkd.in/esTdVgJG Rede D’Or will implement PathAI’s AISight® Image Management System across its #pathology operations which support the national network of 78 #hospitals. The platform integrates advanced AI algorithms, including PathAI’s AIM-Breast Biomarker panel supporting ER, PR, HER2, and Ki67 quantification, to support #pathologyworkflows. Rede D’Or will also utilize PathAI’s tools for research purposes. 💬 “This partnership demonstrates how leading healthcare institutions can successfully integrate digital and computational solutions to improve operational efficiency and advance research capabilities to deepen our understanding of diseases and refine treatment approaches,” said Andrew Beck, MD, PhD, co-founder and CEO of PathAI. “Rede D’Or’s commitment to innovation in healthcare as a means to improve patient outcomes makes them the ideal partner for introducing our technology to the Latin American market.” #healthtech #biotech #partnership .......... AIM-IHC Breast Panel is for Research Use Only, not for use in diagnostic procedures. AISight® is for Research Use Only in the US; AISight® Dx is CE-IVD marked in the EEA, UK, and Switzerland.

🌐 PathAI scientists and partners have recently published “Impact of a #machinelearning-powered algorithm on pathologist #HER2 #IHC scoring in #breastcancer” in medRxiv. 📝 Read the publication: https://lnkd.in/gwj454RX #Biomarker assessment is essential for #clinicaltrial enrollment and endpoint assessment as well as for optimal treatment determination in patients with #breastcancer. While manual pathologist scoring remains the standard for predicting HER2 #immunohistochemistry (IHC) status, there is an opportunity to improve inter-pathologist consistency for HER2 scoring. In this paper, we detail the development of an #AIPathology tool, designed to assist researchers by providing interpretable scores of HER2 IHC, consistent with ASCO/CAP guidelines, using digitized whole slide images. Use of this model as an “AI-assist” tool improved inter-pathologist agreement and positive percent agreement overall and at the 0/1+ and 1+/2+ scoring cutoffs. We also show that when interacting with this tool, pathologists overrode the model’s suggestion at varying rates, with the quality of a pathologist’s overrides being correlated with their manual accuracy. #AI #digitalpathology #Pathology

Want to learn more about our new PathAssist Derm tool for #dermatopathology research? We sat down with Santhosh Balasubramanian, Director of #AI Products at PathAI, to discuss: 🔬 The unique challenges in #dermatology & skin #cancer research 🔍 Why PathAI made the move into dermatopathology  🔑 Key features of PathAssist Derm for researchers 🌐 The ways AI is poised to help dermatopathology researchers  and benefit the field 💬 Read our full Q&A with Santhosh and let us know what you think in the comments about dermatopathology and the state of the field today. - Learn more about PathAssist Derm: https://lnkd.in/eB3M5tZZ - Reach out to us for a free demo: digitaldx@pathai.com ........ #AIPathology #Biotech #HealthTech #Pathology #DigitalPathology #SkinCancer #Cancer PathAssist Derm is for research use only. Not for use in diagnostic procedures.

🖥️ 🖱️ Meet your new #AI #dermatopathology research assistant: PathAssist Derm. Now available on the AISight® Image Management System, designed to streamline your #skincancer research and #digitalpathology workflows. 💡 Learn more: https://lnkd.in/eB3M5tZZ 🗓️ Schedule a demo today: https://lnkd.in/eSiWeaaf This advanced tool is purpose-built to assist researchers with precise, scalable, and efficient dermatopathology workflows, focusing on: ✔️ Automated Orientation: Quickly aligns tissue sections, eliminating the manual slide adjustments traditionally required. ✔️ AI Classification: Differentiates melanocytic, basaloid, and squamous lesions, including subtypes such as melanoma in situ (MIS), invasive #melanoma, and squamous cell carcinoma. ✔️ Quantitative Analysis: Provides calibrated measurements of the lesion, ensuring data consistency across large-scale studies. ✔️ Ancillary Testing Recommendations: Guides researchers with relevant ancillary stains tailored to specific lesion types. 🔎 PathAssist Derm is multi-scanner compatible and supports high-throughput H&E analysis, enabling researchers to sort and prioritize worklists based on AI-predicted lesion classifications. This capability significantly reduces manual assessments, speeds up research workflows, and helps uncover actionable insights in #skincancer research. #Biotech #AIpathology #cancer #cancerresearch #USCAP ................... PathAssist Derm for research use only. Not for use in diagnostic procedures. AISight® is for Research Use Only in the US; AISight® Dx is CE-IVD marked in the EEA, UK, and Switzerland.

Introducing PathAssist Derm: Your new #AI #dermatopathology research assistant is now available on the AISight® #IMS platform. PathAssist Derm is designed to streamline research workflows by assisting with specimen orientation, sample prioritization, and measurement, driving greater efficiency in #skincancer research. 📣 Read the Announcement: https://lnkd.in/eNs3VnAu With #skincancer affecting over 1.5 million people annually, and #melanoma causing 60,000 deaths each year, the need for innovation in #diagnosticresearch has never been greater. Leveraging #AI, this innovative tool assists dermatopathology researchers by: ✔️ Automating specimen orientation, removing the need for manual glass slide adjustments ✔️ Identifying and characterizing 17 skin lesion types, from common entities like #basalcellcarcinoma to rarer ones like melanoma ✔️ Providing precise lesion measurements to support deeper insights 💡 Learn more about PathAssist Derm: https://lnkd.in/eB3M5tZZ 💬 As Andrew Beck, Co-Founder & CEO of PathAI, says: "These statistics present a critical opportunity for innovation in skin cancer diagnostics and therapeutic research. Our goal with PathAssist Derm is to provide researchers with a scalable tool that enhances dermatopathology research through AI-enabled lesion characterization and workflow efficiency, as part of our overall vision to improve patient outcomes with AI-powered #pathology." PathAssist Derm is just one part of the growing suite of AI-powered solutions available on AISight®, our intelligent enterprise workflow platform. With each new offering, we aim to streamline pathology workflows, reduce manual tasks, and enable groundbreaking research. #USCAP #USCAP2025 #biotechnews ............... PathAssist Derm for research use only. Not for use in diagnostic procedures. AISight® is for Research Use Only in the US; AISight® Dx is CE-IVD marked in the EEA, UK, and Switzerland.

It’s been great being part of Friends’ #DigitalPATHProject working group over the last year we are excited to have PathAI Director of AI Products, Santhosh Balasubramanian, be a panelist during Friends of Cancer Research's public meeting “Advancing the Future of #Diagnostics and #Regulatory Innovations” to share our findings.    The session, entitled “#DigitalPathology and #AI in Diagnostics” will focus on:    ✔️ Implications of AI in diagnostic accuracy and reproducibility ✔️ Developing reference datasets for evaluating digital pathology tools ✔️ Regulatory considerations and future directions    Additionally, this session will include new data from the Digital PATH Project. Join in-person, or online! 🎟️ Register here: bit.ly/4efR4R3 #AIOncology #AIPathology

PathAI explores how laboratories worldwide are transitioning to digital pathology and the business case behind it. This whitepaper examines key aspects of this transformation, including the differences between digital and manual workflows, the costs involved, and the financial impact of going digital. It also highlights how PathAI’s image management system and AI applications enhance efficiency through workflow optimization, case prioritization, quality control, and biomarker quantitation. The whitepaper includes real-world case studies from institutions across the U.S., Europe, and South America, demonstrating how PathAI’s technology is driving measurable value in pathology. You can find the full paper on Pathology News: https://lnkd.in/e9__MbrC #digitalpathology #pathologynews

🤝 Welcome to the PathAI network, Annapath, Inc.! We are thrilled to be partnering with Annapath Pathology Services, a surgical #pathology and #cytopathology lab with specialties in #GI, GU, and #Dermatopathology based in the mid-Atlantic region and now rapidly expanding nationwide. Through this collaboration, Annapath will deploy the AISight® Image Management System, our cutting-edge AI-powered pathology platform, to enhance their lab workflows as well as PathAI’s #AI products to drive improved efficiency and elevate their offerings to customers. 💬 “Annapath is excited to partner with PathAI and adopt the #AISight IMS to drive our #digitalpathology initiatives.” said Craig Zwobot, Vice President of Annapath. “The AISight IMS will streamline our #histopathology workflows, enabling peer review and discussion of difficult cases in seconds, instead of hours or days while enhancing our ability to share the images with the referring providers.” We look forward to working closely with Annapath to transform #AIpathology together! Fuel your pathology lab with AISight®: https://lnkd.in/ef5NWxse Reach out to us: digitaldx@pathai.com ………. AISight® is for Research Use Only in the US; AISight® Dx is CE-IVD marked in the EEA, UK, and Switzerland